当前位置: 首页 >> 检索结果
共有 3921 条符合本次的查询结果, 用时 6.2518316 秒

2501. Biochemical and molecular basis of alcohol-induced injury to liver and other tissues.

作者: C S Lieber.
来源: N Engl J Med. 1988年319卷25期1639-50页

2502. Converting-enzyme inhibitors in the treatment of hypertension.

作者: G H Williams.
来源: N Engl J Med. 1988年319卷23期1517-25页

2503. Health effects of involuntary smoking.

作者: J E Fielding.;K J Phenow.
来源: N Engl J Med. 1988年319卷22期1452-60页

2504. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction.

作者: N L Benowitz.
来源: N Engl J Med. 1988年319卷20期1318-30页

2505. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2).

作者: R W Schrier.
来源: N Engl J Med. 1988年319卷17期1127-34页
This article has analyzed the pathogenesis of sodium and water retention in several circumstances. The initiator of retention has been proposed to be either a fall in cardiac output (e.g., low-output cardiac failure and vasoconstrictor hypovolemic nephrotic syndrome) or peripheral arterial vasodilatation (e.g., high-output cardiac failure, cirrhosis, arteriovenous fistula, and pregnancy). In the only state discussed, in which the kidney is diseased and not merely responding to extrarenal reflexes--i.e., nephrotic syndrome--intrarenal mechanisms may predominate and lead to expansion of the arterial vascular tree and suppression of the renin-angiotensin-aldosterone system (i.e., hypervolemic nephrotic syndrome). Otherwise, when kidneys are healthy, either a fall in cardiac output or peripheral arterial vasodilatation may diminish arterial vascular filling and thereby initiate a series of hemodynamic and hormonal events that result in renal sodium and water retention (Fig. 7). Finally, the approach presented in this article should be considered to be a vantage point from which to evaluate states of sodium and water retention, but not to be an exclusive position.

2506. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1).

作者: R W Schrier.
来源: N Engl J Med. 1988年319卷16期1065-72页

2507. The molecular genetics of Philadelphia chromosome-positive leukemias.

作者: R Kurzrock.;J U Gutterman.;M Talpaz.
来源: N Engl J Med. 1988年319卷15期990-8页

2508. Tissue plasminogen activator.

作者: J Loscalzo.;E Braunwald.
来源: N Engl J Med. 1988年319卷14期925-31页

2509. Current concepts. Acute mountain sickness.

作者: T S Johnson.;P B Rock.
来源: N Engl J Med. 1988年319卷13期841-5页

2510. Clinical implications of prostaglandin and thromboxane A2 formation (2).

作者: J A Oates.;G A FitzGerald.;R A Branch.;E K Jackson.;H R Knapp.;L J Roberts.
来源: N Engl J Med. 1988年319卷12期761-7页

2511. Clinical implications of prostaglandin and thromboxane A2 formation (1).

作者: J A Oates.;G A FitzGerald.;R A Branch.;E K Jackson.;H R Knapp.;L J Roberts.
来源: N Engl J Med. 1988年319卷11期689-98页

2512. Prerenal failure: a deleterious shift from renal compensation to decompensation.

作者: K F Badr.;I Ichikawa.
来源: N Engl J Med. 1988年319卷10期623-9页

2513. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide.

作者: A E Broadus.;M Mangin.;K Ikeda.;K L Insogna.;E C Weir.;W J Burtis.;A F Stewart.
来源: N Engl J Med. 1988年319卷9期556-63页

2514. Ipratropium bromide.

作者: N J Gross.
来源: N Engl J Med. 1988年319卷8期486-94页

2515. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2).

作者: P W Gold.;F K Goodwin.;G P Chrousos.
来源: N Engl J Med. 1988年319卷7期413-20页
Thousands of studies have been conducted of the functioning of the many neurotransmitter systems in order to explore the biologic basis of major depressive disorder. Instead of reviewing this literature exhaustively, we have attempted to propose a model that accommodates the clinical observation that chronic stress early in life in vulnerable persons predisposes them to major depression with contemporary observations of the potential consequences of repeated central nervous system exposure to effectors of the stress response. This model accords with current clinical judgment that major depression is best treated with a combination of psychopharmacologic agents and psychotherapy. Accordingly, whereas psychopharmacologic intervention may be required to resolve an active episode of major depression and to prevent recurrences, psychotherapy may be equally important to lessen the burden of stress imposed by intense inner conflict and counterproductive defenses.

2516. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1).

作者: P W Gold.;F K Goodwin.;G P Chrousos.
来源: N Engl J Med. 1988年319卷6期348-53页

2517. Corticotropin-releasing hormone.

作者: A L Taylor.;L M Fishman.
来源: N Engl J Med. 1988年319卷4期213-22页

2518. Pediatric surgery.

作者: W H Hendren.;C W Lillehei.
来源: N Engl J Med. 1988年319卷2期86-96页

2519. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

作者: S M Grundy.
来源: N Engl J Med. 1988年319卷1期24-33页

2520. Restenosis after successful coronary angioplasty. Pathophysiology and prevention.

作者: W McBride.;R A Lange.;L D Hillis.
来源: N Engl J Med. 1988年318卷26期1734-7页
共有 3921 条符合本次的查询结果, 用时 6.2518316 秒